EYEN Eyenovia Inc.

2.85
+0.04  (+1%)
Previous Close 2.81
Open 2.89
52 Week Low 1.11
52 Week High 5.0593
Market Cap $56,361,654
Shares 19,776,019
Float 12,949,014
Enterprise Value $42,357,687
Volume 82,664
Av. Daily Volume 63,820
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
MicroStat
Mydriasis - pupil dilation
NDA Filing
NDA Filing
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
MicroPine - CHAPERONE
Myopia
Phase 3
Phase 3
Phase 3 resumption of enrolment following COVID-19 announced June 30, 2020.
MicroLine
Presbyopia
Phase 3
Phase 3
Phase 3 trial to be initiated in 2020.
MicroProst
Chronic angle closure glaucoma (CACG)
Phase 2
Phase 2
Development to be deferred - noted October 29, 2019.

Latest News

  1. NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company has resumed patient enrollment for its Phase III CHAPERONE study for the treatment of progressive myopia, following a temporary pause due to the COVID-19 pandemic. 

    "We are excited to resume enrollment in our Phase III CHAPERONE study among nearly all of our clinical sites for the treatment of progressive myopia in children.  Despite conditions caused by COVID-19, we continued to follow-up with and monitor previously enrolled CHAPERONE patients via telemedicine and remote monitoring processes.  We are pleased to report…

    NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company has resumed patient enrollment for its Phase III CHAPERONE study for the treatment of progressive myopia, following a temporary pause due to the COVID-19 pandemic. 

    "We are excited to resume enrollment in our Phase III CHAPERONE study among nearly all of our clinical sites for the treatment of progressive myopia in children.  Despite conditions caused by COVID-19, we continued to follow-up with and monitor previously enrolled CHAPERONE patients via telemedicine and remote monitoring processes.  We are pleased to report that all patients previously randomized to treatment have continued to progress in the study. We are working in close partnership with our investigational sites as we advance to complete trial enrollment, which will depend on the continued improvement of the COVID-19 pandemic," commented Dr. Sean Ianchulev, Eyenovia's Chief Executive Officer and Chief Medical Officer. " 

    The CHAPERONE study is a U.S.-based, multi-center, randomized, double-masked trial that will enroll more than 400 children between 3-12 years of age. The study is investigating the safety and efficacy of MicroPine for the reduction of progressive myopia using Eyenovia's proprietary atropine topical micro-formulation delivered by the Optejet™ dispenser. Subjects will be randomized to receive treatment with either of two MicroPine concentrations or a placebo. The primary endpoint of the study is the proportion of eyes with < 0.5 D increase in refractive error from baseline through 36 months.

    About Eyenovia

    Eyenovia, Inc. (NASDAQ:EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia's pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information please visit www.eyenovia.com.

    About MicroPine for Progressive Myopia

    MicroPine (atropine ophthalmic solution) is Eyenovia's first-in-class topical treatment for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness. Progressive myopia is estimated to affect close to 5 million children in the United States who suffer from uncontrolled axial elongation of the sclera leading to increasing levels of myopia and in some cases major pathologic changes such as retinal atrophy, macular staphylomas, retinal detachment and visual impairment. MicroPine has been developed for comfort and ease-of-use in children. Microdose administration of MicroPine is anticipated to result in low systemic and ocular drug exposure. A recent therapeutic evidence assessment and review by the American Academy of Ophthalmology indicates Level 1 (highest) evidence of efficacy for the role of low dose atropine for progressive myopia (Ophthalmology 2017;124:1857-1866; Ophthalmology 2016; 123(2) 391:399).

    Feasibility Dose-finding Atropine Studies: ATOM 1; ATOM 2; LAMP (Independent Collaborative Group Trials)

    About MicroLine for Presbyopia

    MicroLine is Eyenovia's pharmacologic treatment for presbyopia. Presbyopia is the non-preventable, age related hardening of the lens, which causes a gradual loss of the eye's ability to focus on nearby objects and is estimated to affect nearly 113 million Americans. Current treatment options are typically device-based, such as reading glasses and contact lenses. Pilocarpine ophthalmic solution is known to constrict the pupil and improve near-distance vision by creating an extended depth of focus through its small aperture effect. Eyenovia believes that its administration of pilocarpine using the company's high precision microdosing technology may provide a meaningful improvement in near vision while enhancing tolerability and usability.

    About MicroStat for Mydriasis

    MicroStat is Eyenovia's first-in-class fixed-combination micro-formulation product (tropicamide 1% - phenylephrine 2.5%) candidate for pharmacologic mydriasis (eye dilation), which is targeted to improve the efficiency of the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the United States, as well as the estimated 4 million pharmacologic mydriasis applications for cataract surgery. Developed for use without anesthetic, we are developing MicroStat to improve the efficacy and tolerability of pharmacologic mydriasis.

    About Optejet™ and MicroRx Ocular Therapeutics

    Eyenovia's Optejet microdose formulation and delivery platform for ocular therapeutics uses high-precision piezo-print technology to deliver approximately 8 μL of drug, consistent with the capacity of the tear film of the eye. We believe the volume of ophthalmic solution administered with the Optejet is less than 75% of that delivered using conventional eyedroppers, thus reducing overdosing and exposure to drug and preservatives. Eyenovia's patented microfluidic ejection technology is designed for fast and gentle ocular surface delivery, where solution is dispensed to the ocular surface in approximately 80 milliseconds, beating the ocular blink reflex. Successful use of the Optejet has been demonstrated more than 85% of the time after basic training in a variety of clinical settings compared to 40 – 50% with conventional eyedroppers. Additionally, its smart electronics and mobile e-health technology are designed to track and enhance patient compliance.

    Forward Looking Statements

    Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities in the United States for our product candidates. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the SEC. In addition, such statements could be affected by risks and uncertainties related to, among other things: impacts of and uncertainty related to COVID-19; risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing and our ability to submit applications for, obtain and maintain regulatory approvals for our product candidates; fluctuations in our financial results, particularly given market conditions and the potential economic impact of COVID-19; our need to raise additional money to fund our operations for at least the next 12 months as a going concern; the potential impacts of COVID-19 on our supply chain; the potential success of our reprioritized pipeline; any cost savings related to our reprioritized pipeline; our estimates regarding the potential market opportunity for our product candidates; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; our ability to timely develop and implement anticipated manufacturing, commercialization and marketing capabilities and strategies for existing product candidates; our ability to attract and retain key personnel; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, we do not undertake any obligation to update any forward-looking statements.

    Company Contact:

    Eyenovia, Inc.

    John Gandolfo

    Chief Financial Officer

    Investor Contact:

    The Ruth Group

    Tram Bui / Alexander Lobo

    Phone: 646-536-7035/7037

    /

    Media Contact:

    The Ruth Group

    Kirsten Thomas

    Phone: 508-280-6592

    Primary Logo

    View Full Article Hide Full Article
  2. NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it adjourned its 2020 Annual Meeting of Stockholders (the "Annual Meeting") originally scheduled to be held on June 11, 2020 at 9:00 a.m., EDT to June 30, 2020 at 9:00 a.m., EDT, to be conducted in a virtual-only format, via live webcast (the "Adjourned Annual Meeting").

    Stockholders will not be able to physically attend the Adjourned Annual Meeting in person. Stockholders at the close of business on the record date, April 15, 2020, are entitled to participate in the Adjourned Annual Meeting…

    NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it adjourned its 2020 Annual Meeting of Stockholders (the "Annual Meeting") originally scheduled to be held on June 11, 2020 at 9:00 a.m., EDT to June 30, 2020 at 9:00 a.m., EDT, to be conducted in a virtual-only format, via live webcast (the "Adjourned Annual Meeting").

    Stockholders will not be able to physically attend the Adjourned Annual Meeting in person. Stockholders at the close of business on the record date, April 15, 2020, are entitled to participate in the Adjourned Annual Meeting by means of remote communication. Stockholders and their proxy holders may be deemed present in person and will be able to listen to the Adjourned Annual Meeting live, vote, and submit questions via means of remote communication as set forth below.

    To be admitted to the Adjourned Annual Meeting, stockholders should visit www.virtualshareholdermeeting.com/EYEN2020, and must enter the 16-digit voting control number found in the proxy materials previously sent to stockholders. The Company encourages stockholders to access the Adjourned Annual Meeting prior to the start time. Online check-in will begin at 8:45 a.m., EDT. Stockholders should allow ample time for check-in procedures. A list of stockholders entitled to vote at the Adjourned Annual Meeting will be available and open to examination during the entirety of the Adjourned Annual Meeting in accordance with Delaware law at www.virtualshareholdermeeting.com/EYEN2020. If stockholders encounter any difficulties accessing the Adjourned Annual Meeting during the check-in or meeting time, please call the technical support number that will be available at www.virtualshareholdermeeting.com/EYEN2020.

    Please note that the proxy card and voting instruction card included with previously-distributed proxy materials will not be updated to reflect the adjournment from an in-person meeting to a virtual-only meeting, and may continue to be used to vote shares in connection with the Adjourned Annual Meeting. For additional information regarding how stockholders may access, vote, and participate in the virtual Adjourned Annual Meeting, please refer to the Company's supplemental proxy materials filed today with the U.S. Securities and Exchange Commission.

    Whether or not a stockholder plans to attend the virtual-only Adjourned Annual Meeting, the Company urges each stockholder to vote and submit his or her proxy in advance of the meeting by one of the methods described in the proxy materials.

    About Eyenovia

    Eyenovia, Inc. (NASDAQ:EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology. Eyenovia's pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information please visit www.eyenovia.com.

    Company Contact:

    Eyenovia, Inc.

    John Gandolfo

    Chief Financial Officer



    Investor Contact:

    The Ruth Group

    Tram Bui / Alexander Lobo

    Phone: 646-536-7035/7037

     /

    Primary Logo

    View Full Article Hide Full Article
  3. NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it intends to convene and immediately adjourn its 2020 Annual Meeting of Stockholders (the "Annual Meeting") scheduled to be held on June 11, 2020 at 9:00 a.m., EDT to June 30, 2020 at 9:00 a.m., EDT, and that the adjourned meeting will be conducted exclusively in a virtual-only format by means of remote communication. Stockholders and their proxy holders will not be able to physically attend the adjourned Annual Meeting in person, however, stockholders and their proxy holders may be deemed…

    NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it intends to convene and immediately adjourn its 2020 Annual Meeting of Stockholders (the "Annual Meeting") scheduled to be held on June 11, 2020 at 9:00 a.m., EDT to June 30, 2020 at 9:00 a.m., EDT, and that the adjourned meeting will be conducted exclusively in a virtual-only format by means of remote communication. Stockholders and their proxy holders will not be able to physically attend the adjourned Annual Meeting in person, however, stockholders and their proxy holders may be deemed present in person and will be able to vote and ask questions during the adjourned Annual Meeting by means of remote communication through the online platform.

    The decision to adjourn the Annual Meeting and hold it in a virtual-only format was made in light of the public health and safety concerns related to the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of the Company's stockholders, employees, and community. The means of remote communication by which stockholders and proxy holders may be deemed to be present in person and vote at the adjourned Annual Meeting will be forthcoming in a press release and also made available under the Investors – Financials – Annual Meeting Materials section of our website at www.eyenovia.com after the Annual Meeting is adjourned.

    About Eyenovia

    Eyenovia, Inc. (NASDAQ:EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology. Eyenovia's pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information please visit www.eyenovia.com.

    Company Contact:

    Eyenovia, Inc.

    John Gandolfo

    Chief Financial Officer

    Investor Contact:

    The Ruth Group

    Tram Bui / Alexander Lobo

    Phone: 646-536-7035/7037

    /

    Media Contact:

    The Ruth Group

    Kirsten Thomas

    Phone: 508-280-6592

    Primary Logo

    View Full Article Hide Full Article
  4. NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the first quarter ended March 31, 2020.

    First Quarter 2020 and Recent Business Highlights

    • Successfully completed a private placement of units comprised of common stock and warrants with aggregate net proceeds to the Company of approximately $5.4 million in March 2020;
    • Amended its Exclusive License Agreement with Senju Pharmaceutical Co., Ltd. allowing Eyenovia to license certain of its products in China (including, Hong Kong, Macao and Taiwan) and South Korea; and
    • Experiencing…

    NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the first quarter ended March 31, 2020.

    First Quarter 2020 and Recent Business Highlights

    • Successfully completed a private placement of units comprised of common stock and warrants with aggregate net proceeds to the Company of approximately $5.4 million in March 2020;
    • Amended its Exclusive License Agreement with Senju Pharmaceutical Co., Ltd. allowing Eyenovia to license certain of its products in China (including, Hong Kong, Macao and Taiwan) and South Korea; and
    • Experiencing delays in initiation of MicroLine Phase III studies for presbyopia and completion of enrollment of MicroPine Phase III study for progressive myopia due to global COVID-19 pandemic.

    "In the first quarter of 2020, we successfully strengthened our balance sheet with our private placement, which should fund the Company's operations into 2021. Looking ahead, we are preparing to submit our New Drug Application for MicroStat to the FDA this year, as well as anticipate initiating our Phase III trials for MicroLine when the environment becomes safe to do so. We also look forward to re-initiating enrollment of our MicroPine Phase III trial, and in the interim, will continue to supply cartridges of MicroPine by mail and work with our clinical partners to follow-up virtually with previously enrolled study participants," commented Dr. Sean Ianchulev, Eyenovia's Chief Executive Officer and Chief Medical Officer. "Our priority remains the health and safety of our employees, patients, and partners as well as the communities they serve. We believe that our fearless Eyenovia spirit of ingenuity and resilience will help ensure that we persevere through this period of uncertainty."

    First Quarter 2020 Financial Review

    For the first quarter of 2020, net loss was approximately $5.5 million, or $(0.31) per share, compared to a net loss of approximately $5.9 million, or $(0.50) per share for the first quarter of 2019.

    Research and development expenses totaled approximately $3.6 million for the first quarter of 2020, compared to approximately $4.0 million for the same period in 2019, a decrease of approximately 9.3%.

    For the first quarter of 2020, general and administrative expenses were approximately $1.8 million compared to approximately $1.9 million for the first quarter of 2019, a decrease of approximately 5.5%.

    Total operating expenses for the first quarter of 2020 were approximately $5.5 million, compared to total operating expenses of approximately $6.0 million for the same period in 2019, a decrease of approximately 8.1%.

    As of March 31, 2020, the Company's cash balance was approximately $13.7 million. This includes approximately $5.4 million of net proceeds from Eyenovia's private placement, which closed in March 2020.

    Conference Call and Webcast

    The conference call is scheduled to begin at 4:45pm ET on Wednesday, May 13, 2020. Participants should dial 1-866-916-2921 (United States) or 1-210-874-7771 (International) with the conference code 4397339. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com.

    After the live webcast, the event will be archived on Eyenovia's website for one year. In addition, a telephonic replay of the call will be available until May 20, 2020. The replay can be accessed by dialing 1-855-859-2056 (United States) or 1-404-537-3406 (International) with confirmation code 4397339.

    About Eyenovia
    Eyenovia, Inc. (NASDAQ:EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology. Eyenovia's pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information please visit www.eyenovia.com.

    About MicroLine for Presbyopia
    MicroLine is Eyenovia's pharmacologic treatment for presbyopia. Presbyopia is the non-preventable, age related hardening of the lens, which causes a gradual loss of the eye's ability to focus on nearby objects and is estimated to affect nearly 113 million Americans. Current treatment options are typically device-based, such as reading glasses and contact lenses. Pilocarpine ophthalmic solution is known to constrict the pupil and improve near-distance vision by creating an extended depth of focus through its small aperture effect. Eyenovia believes that its administration of pilocarpine using the company's high precision microdosing technology could provide a meaningful improvement in near vision while enhancing tolerability and usability.

    About MicroPine for Progressive Myopia
    MicroPine (atropine ophthalmic solution) is Eyenovia's first-in-class topical treatment for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness. Progressive myopia is estimated to affect close to 5 million children in the United States who suffer from uncontrolled axial elongation of the sclera leading to increasing levels of myopia and in some cases major pathologic changes such as retinal atrophy, macular staphylomas, retinal detachment and visual impairment. MicroPine has been developed for comfort and ease-of-use in children. Microdose administration of MicroPine is anticipated to result in low systemic and ocular drug exposure. A recent therapeutic evidence assessment and review by the American Academy of Ophthalmology indicates Level 1 (highest) evidence of efficacy for the role of low dose atropine for progressive myopia (Ophthalmology 2017;124:1857-1866; Ophthalmology 2016; 123(2) 391:399).

    Feasibility Dose-finding Atropine Studies: ATOM 1; ATOM 2; LAMP (Independent Collaborative Group Trials)

    About MicroStat for Mydriasis
    MicroStat is Eyenovia's first-in-class fixed-combination micro-formulation product (phenylephrine 2.5% -tropicamide 1%) candidate for pharmacologic mydriasis (eye dilation), which is targeted to improve the efficiency of the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the United States, as well as the estimated 4 million pharmacologic mydriasis applications for cataract surgery. Developed for use without anesthetic, we are developing MicroStat to improve the efficacy and tolerability of pharmacologic mydriasis.

    About Optejet™ and MicroRx Ocular Therapeutics
    Eyenovia's Optejet microdose formulation and delivery platform for ocular therapeutics uses high-precision piezo-print technology to deliver 6-8 μL of drug, consistent with the capacity of the tear film of the eye. We believe the volume of ophthalmic solution administered with the Optejet is less than 75% of that delivered using conventional eyedroppers, thus reducing overdosing and exposure to drug and preservatives. Eyenovia's patented microfluidic ejection technology is designed for fast and gentle ocular surface delivery, where solution is dispensed to the ocular surface in approximately 80 milliseconds, beating the ocular blink reflex. Successful use of the Optejet has been demonstrated more than 85% of the time after basic training in a variety of clinical settings compared to 40 – 50% with conventional eyedroppers. Additionally, its smart electronics and mobile e-health technology are designed to track and enhance patient compliance.

    Forward Looking Statements
    Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities in the United States for our product candidates. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the SEC. In addition, such statements could be affected by risks and uncertainties related to, among other things: impacts of and uncertainty related to COVID-19; fluctuations in our financial results, particularly given market conditions and the potential economic impact of COVID-19; our need to raise additional money to fund our operations for at least the next 12 months as a going concern; the potential impacts of COVID-19 on our supply chain; risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could continue to be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing and our ability to submit applications for, obtain and maintain regulatory approvals for our product candidates; the potential success of our reprioritized pipeline; any cost savings related to our reprioritized pipeline; our estimates regarding the potential market opportunity for our product candidates; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; our ability to timely develop and implement anticipated manufacturing, commercialization and marketing capabilities and strategies for existing product candidates; our ability to attract and retain key personnel; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, we do not undertake any obligation to update any forward-looking statements.

    Company Contact:
    Eyenovia, Inc.
    John Gandolfo
    Chief Financial Officer

    Investor Contact:
    The Ruth Group
    Tram Bui / Alexander Lobo
    Phone: 646-536-7035/7037
    /

    Media Contact:
    The Ruth Group
    Kirsten Thomas
    Phone: 508-280-6592

    (Financial Statements to Follow)

    EYENOVIA, INC.
             
    Condensed Balance Sheets
         
        March 31,   December 31,
        2020
      2019
        (unaudited)    
             
             
             
    Current Assets:        
    Cash $ 13,656,091     $ 14,152,601  
    Prepaid expenses and other current assets   860,917       196,680  
             
    Total Current Assets   14,517,008       14,349,281  
             
    Property and equipment, net   273,739       230,538  
    Security deposit     117,800       117,800  
             
    Total Assets $ 14,908,547     $ 14,697,619  
             
    Liabilities and Stockholders' Equity      
             
    Current Liabilities:      
    Accounts payable $ 1,252,758     $ 1,541,358  
    Accrued compensation   348,009       916,873  
    Accrued expenses and other current liabilities   513,963       453,430  
    Short term note payable   423,165       -  
             
    Total Current Liabilities   2,537,895       2,911,661  
             
    Deferred rent     45,348       45,351  
             
    Total Liabilities   2,583,243       2,957,012  
             
    Commitments and contingencies      
             
    Stockholders' Equity:      
    Preferred stock, $0.0001 par value, 6,000,000 shares authorized;      
    0 shares issued and outstanding as of March 31, 2020 and      
    as of December 31, 2019   -       -  
    Common stock, $0.0001 par value, 90,000,000 shares authorized;      
    19,776,019 and 17,100,726 shares issued and outstanding      
    as of March 31, 2020 and December 31, 2019, respectively   1,977       1,710  
    Additional paid-in capital   75,445,289       69,409,949  
    Accumulated deficit   (63,121,962 )     (57,671,052 )
             
    Total Stockholders' Equity   12,325,304       11,740,607  
             
    Total Liabilities and Stockholders' Equity $ 14,908,547     $ 14,697,619  


    EYENOVIA, INC.
           
    Condensed Statements of Operations
    (unaudited)
           
       For the Three Months Ended
       March 31,
      2020   2019
           
    Operating Expenses:      
    Research and development $ 3,634,287     $ 4,008,896  
    General and administrative   1,836,782       1,942,763  
           
    Total Operating Expenses   5,471,069       5,951,659  
           
    Loss From Operations   (5,471,069 )     (5,951,659 )
           
    Other Income:      
    Interest expense   (3,681 )     -  
    Interest income   23,840       19,275  
           
    Net Loss $ (5,450,910 )   $ (5,932,384 )
           
    Net Loss Per Share      
    - Basic and Diluted $ (0.31 )   $ (0.50 )
           
    Weighted Average Number of      
    Common Shares Outstanding      
    - Basic and Diluted   17,308,804       11,919,973  

     

     

    Primary Logo

    View Full Article Hide Full Article
  5. Knoxville, Tennessee, May 06, 2020 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies, Inc. ("HITC") is pleased to announce the addition of Jurgen Vollrath as its outside counsel for Intellectual Property ("IP") to its growing team of professionals. Mr. Vollrath, who has spent the past 30 years working with technology firms ranging from startups to Fortune 100 companies, is recognized as a leading IP strategist. His previous experience includes leading National Semiconductor's licensing, IP due diligence, and Trademarks teams, serving as managing partner of Arter & Hadden's patent group, and holding the position of Chief IP Officer of SAP, where he secured its global cross license with Microsoft and positioned them to become the world…

    Knoxville, Tennessee, May 06, 2020 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies, Inc. ("HITC") is pleased to announce the addition of Jurgen Vollrath as its outside counsel for Intellectual Property ("IP") to its growing team of professionals. Mr. Vollrath, who has spent the past 30 years working with technology firms ranging from startups to Fortune 100 companies, is recognized as a leading IP strategist. His previous experience includes leading National Semiconductor's licensing, IP due diligence, and Trademarks teams, serving as managing partner of Arter & Hadden's patent group, and holding the position of Chief IP Officer of SAP, where he secured its global cross license with Microsoft and positioned them to become the world leader in enterprise software. More recently, he co-founded and served as CEO of Coninthian Ophthalmic (NASDAQ:EYEN). Mr. Vollrath currently supports tech startups as general partner and advisor at Avenurine, a technology incubator and fund management company located in Portland, Oregon. Before embarking on his career as a patent attorney, Jurgen served in the Air Force as JAG officer, rising to the rank of First Lieutenant.

    Healthcare Integrated Technologies realizes the importance of a centralized and proactive management of all IP activities including, portfolio administration, litigation, mergers and acquisitions, licensing, and monetization, and is excited to add Mr. Vollrath to its team.

    "IP is a key strategic driver and an important source of value creation for HITC. Jurgen Vollrath has a proven track record as one of the world's best IP experts," said Scott M. Boruff, CEO.

    About Healthcare Integrated Technologies, Inc.

    Healthcare Integrated Technologies, Inc. is focused on developing effective, non-intrusive, resident monitoring technologies for senior living communities. Healthcare Integrated Technologies is headquartered in Knoxville, Tennessee. More information on HITC can be found at www.getinde.com.

    Statements Regarding Forward-Looking Information

    Certain statements contained herein are forward-looking statements including, but not limited to, statements that are predications of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties. Forward-looking statements are not guarantees of future activities and are subject to many risks and uncertainties. Due to such risks and uncertainties, actual events may differ materially from those reflected or contemplated in such forward-looking statements. Forward-looking statements can be identified by the use of the future tense or other forward-looking words such as "believe," "expect," "anticipate," "intend," "plan," "should," "may," "will," "continue," "strategy," "position," "opportunity," statements regarding the "flexibility" of the Company or the negative of any of those terms or other variations of them or by comparable terminology. A discussion of these risk factors is included in the Company's periodic reports filed with the SEC.

    Contact:

    Mr. Scott M. Boruff, CEO
    (865) 237-4448

    View Full Article Hide Full Article
View All Eyenovia Inc. News